Overall, these data suggest that targeting NEDD9-associated pathways such as the AURKA-HDAC6-CTTN signaling is a promising strategy for preventing CLL homing, thus limiting disease progression (Fig. 6F). The gene discussed is CTTN; the disease is B-cell chronic lymphocytic leukemia.